目的 探討消糖靈膠囊聯(lián)合利拉魯肽治療肥胖2型糖尿病的臨床療效。方法 選擇2019年12月—2021年6月在河北中石油中心醫(yī)院治療的120例肥胖2型糖尿病患者，隨機(jī)分為對(duì)照組和治療組，每組各60例。對(duì)照組早餐前皮下注射利拉魯肽注射液，0.6 mg/次，1次/d。治療組在對(duì)照組的基礎(chǔ)上口服消糖靈膠囊，3片/次，2次/d。兩組患者連續(xù)用藥15周。觀察兩組患者臨床療效，比較治療前后兩組患者癥狀緩解時(shí)間，血糖指標(biāo)空腹血糖（FPG）、餐后2 h血糖（2 h PBG）、糖化血紅蛋白（HbA1c）和空腹血清胰島素（FINS）水平，血清因子腫瘤壞死因子-α（TNF-α）、可溶性血管細(xì)胞黏附因子-1（Svcam-1）、白細(xì)胞介素-6（IL-6）和超敏C反應(yīng)蛋白（hs-CRP）水平，及不良反應(yīng)。結(jié)果 治療后，治療組總有效率為98.33%，明顯高于對(duì)照組的83.33%（P<0.05）。治療后，治療組多飲、多食、多尿、口干緩解時(shí)間均明顯早于對(duì)照組（P<0.05）。治療后，兩組患者FPG、2 h FPG、HbA1c、FINS指標(biāo)和血清因子TNF-α、Svcam-1、IL-6、hs-CRP水平均明顯下降（P<0.05），且治療后治療組這些指標(biāo)明顯低于對(duì)照組（P<0.05）。治療期間，治療組不良反應(yīng)發(fā)生率為6.67%，明顯低于對(duì)照組的13.33%（P<0.05）。結(jié)論 消糖靈膠囊聯(lián)合利拉魯肽治療肥胖2型糖尿病效果確切，癥狀緩解明顯，并能有效控制患者血糖，降低機(jī)體炎癥反應(yīng)。

Objective To discuss the treatment effect of Xiaotangling Capsules combined with liraglutide in treatment of obesity type 2 diabetes. Methods Patients (120 cases) with obesity type 2 diabetes in Hebei Petro China Central Hospital from December 2019 to June 2021 were randomly divided into control and treatment group, and each group had 60 cases. Patients in the control group were sc administered with Liraglutide Injection before breakfast, 0.6 mg/time, once daily. Patients in the treatment group were po administered with Xiaotangling Capsules on the basis of the control group, 3 tablets/time, twice daily. Patients in two groups were treated for 15 weeks. After treatment, the clinical evaluation was evaluated, the improvement time of symptoms, the levels of blood glucose indexes FBG, 2 h PBG, HbA1c, and FINS, the levels of TNF-α, Svcam-1, IL-6, and hs-CRP, and adverse reactions in two groups. Results After treatment, the clinical effective rate of the treatment group was 98.33%, which was significantly higher than that of the control group (83.33%, P < 0.05). After treatment, the relief time of polydipsia, polydipsia, polyuria, and dry mouth in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the indexes FPG, 2 h FPG, HbA1c, FINS, and the levels of serum factor TNF-α, sVCAM-1, IL-6, and hs-CRP in two groups were significantly decreased (P < 0.05), and the indicators the treatment group were significantly lower than those in the control group (P < 0.05). During the treatment period, the incidence of adverse reactions in the treatment group was 6.67%, significantly lower than 13.33% in the control group (P < 0.05). Conclusion Xiaotangling Capsules combined with liraglutide is effective in treatment of obesity type 2 diabetes with obvious symptom relief, and can effectively control the patient's blood glucose, reduce the inflammatory response,.

R977

廊坊市科技支撐計(jì)劃項(xiàng)目（2019013121）